argenx Achieves First Full Year of Profitability with $4.2B in Net Sales (ARGX Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
argenx marked a historic milestone in 2025, delivering its first full year of operating profitability propelled by the staggering success of its flagship immunology drug, VYVGART. The company reported $4.2 billion in global product net sales for the year, representing a 90% year-over-year growth rate. With $1.3 billion of those sales generated in the fourth quarter alone, argenx exited the year with approximately 19,000 patients on treatment globally. Beyond its exceptional financial performance, the company fortified its leadership in FcRn-targeted therapies by announcing positive topline results from its Phase III ADAPT OCULUS study, paving the way for further label expansion into ocular myasthenia gravis.
Financial Inflection: Profitability and Soaring Sales
2025 was a year of profound commercial execution for argenx. Full-year net product sales hit $4.2 billion, driven heavily by U.S. demand which surged 68% year-over-year in Q4 to $1.1 billion. The successful rollout of the prefilled syringe (PFS) for self-injection was a key catalyst, expanding the prescriber base to over 4,700 clinicians and driving earlier-line adoption for VYVGART. Crucially, the company's top-line hypergrowth outpaced its operational expenses. argenx reported an annual operating profit of $1.1 billion and a total net profit of $1.3 billion for the year. This financial inflection fortified the company's balance sheet, ending 2025 with $4.4 billion in cash, up more than $1 billion year-over-year, providing massive firepower to fund its deep pipeline.
Expanding the Myasthenia Gravis Franchise
argenx continues to consolidate its dominance in the generalized myasthenia gravis (gMG) market—currently capturing 6 out of 10 patients newly starting a biologic. Now, the company is aggressively expanding its label to reach historically underserved MG populations. During the earnings call, argenx announced positive results from the Phase III ADAPT OCULUS study for ocular MG. Patients treated with VYVGART Hytrulo experienced a statistically significant 4.04-point mean improvement in ocular symptoms (ptosis and diplopia) at week 4, compared to a 1.99-point improvement on placebo. Based on these data, argenx plans to file a supplemental Biologics License Application (sBLA). Coupled with the upcoming May 10, 2026, PDUFA date for seronegative MG, argenx is on track to have the broadest label in the MG space, unlocking access to an additional 18,000 patients and bringing its total addressable US MG market to 60,000.
Sustained Momentum in CIDP and Beyond
The launch of VYVGART in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is following the same successful trajectory as its MG rollout. argenx is capturing patients struggling with current therapies, and uptake is accelerating thanks to strong evidence of functional benefit and the convenience of the newly launched prefilled syringe. Q4 saw a major access win for the PFS formulation with UnitedHealthcare, pushing covered lives past 90% in the US.
Looking to the broader pipeline, 2026 promises to be another catalyst-rich year. Management highlighted the upcoming Q4 2026 readout for empasiprubart in Multifocal Motor Neuropathy (MMN)—a head-to-head study against IVIg. If successful, this first-in-class C2 inhibitor would mark argenx's second commercial medicine, further cementing its leadership in severe autoimmune neurology.